Answers are grounded in this paper and cite their sources.
Purpose When to stop breast cancer screening remains uncertain. The USPSTF recommends screening to age 74. Modeling estimates on screening benefit after age 74 are 5-12 average life-years gained (LYG) per 1000 women, which may be a useful benchmark for considering stopping screening. Existing LYG estimates do not incorporate individualized cancer risk or individualized life expectancy and involve numerous assumptions in simulation models. We aimed to estimate screening benefit in older women that incorporate frailty/comorbidity and breast cancer risk. Methods Using SEER-Medicare data (1999-2017), we constructed cohorts to estimate screening benefit at age 70 and 75, respectively. We included women continuously enrolled in fee-for-service Medicare for ≥5 years and were breast cancer free before the age of interest. We obtained screening-associated breast cancer mortality risk reductions from a previous emulated trial. We combined these with individualized breast cancer mortality risk and individualized competing mortality risk to calculate average LYG from continuing annual screening over 8 years. Estimates were stratified by race and comorbidity/frailty. Results Average LYG from screening ranged from 4.7-20.5 life-years per 1000 women in the age 70 cohort (n = 204,288), 3.4-13.6 life-years per 1000 women in the age 75 cohort (n = 193,398). Those with higher comorbidities/frailty had lower average LYG. Those with Hispanic/Asian/other race had the lowest LYG whereas Black women had the highest LYG. Conclusion Average LYGs from breast cancer screening based on population level data are small in older women, with important variations by health status and race, which should be considered in clinical discussions and screening recommendations.
No takes yet. Share an insight, caveat, or question.
Schoenborn et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: